Faruqi and Faruqui, LLP Logo
Share this page

Kite Pharma, Inc. (KITE)

NASDAQ:KITE

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Kite Pharma, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Kite Pharma, Inc. (“Kite” or the “Company”) (NASDAQ:KITE).

The investigation focuses on whether the Company and its executives violated federal securities laws. Specifically, during premarket on May 8, 2017, the Company filed its Form 10-Q with Securities and Exchange Commission disclosing the death of a cancer patient following treatment with the Company's lead product candidate, KTE-C19, a CAR-based therapy that targets the CD19 antigen. The Form 10-Q stated the relevant part: in April 2017, one of the Company’s patients “experienced multi-organ failure, and a neurologic event that subsequently progressed to a fatal grade 5 cerebral edema that was deemed related to axicabtagene ciloleucel [the United States adopted name for KTE-C19 is axicabtagene ciloleucel].”

On this news, the Company’s share price significantly declined, causing harm to investors.

If you invested in Kite stock or options and would like to discuss your legal rights, please fill out the form below.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Kite Pharma, Inc. (KITE)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 05/08/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.